XTL 6865

Drug Profile

XTL 6865

Alternative Names: Anti-HCV dual monoclonal antibody - XTL Biopharmaceuticals; HepeX-C; XTL-6865

Latest Information Update: 01 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XTL Biopharmaceuticals
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 29 Mar 2007 XTL 6865 is available for licensing worldwide (http://www.xtlbio.com)
  • 29 Mar 2007 Results from a phase I clinical trial in patients with chronic hepatitis C added to the adverse events and pharmacokinetics sections
  • 15 Aug 2006 XTL is continuing enrolment in a phase I trial for Hepatitis C infection in the US and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top